Sanofi — Company profile
Healthcare · Drug Manufacturers - General · France
Last price 43.13 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 101.86B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. manufacturing facility in Germany. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Details
| Name | Sanofi |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 74846 |
| Founded | 1994 |
| Ceo | Belen Garijo Lopez |
| Country | France |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| Isin | US80105N1054 |
| Cusip | 80105N105 |
| Cik | 0001121404 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Belen Garijo Lopez M.D. | Chief Executive Officer and Director |
| François-Xavier Roger | Executive Vice President and Chief Financial Officer |
| Dr. Michael Quigley Ph.D. | Chief Scientific Officer and Head of Research |
| Thomas Kudsk Larsen | Head of Investor Relations and General Medicines |
| Jamie Haney | Executive Vice President and General Counsel |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing |
| Veronique Jaillet | Executive Vice President and Interim Chief People Officer |
| Fabrizio Gaudi | Head of Austrian, German and Swiss Operations |
| Erik Wallström | Head of Therapeutic Area - Neurology Development |
| Thomas Triomphe | Executive Vice President of Vaccines |
Contact
| Address | 46, avenue de la Grande ArmEe, Paris, 75017, France |
| Phone | 33 1 53 77 40 00 |
| Website | https://www.sanofi.com |